Synthesis and biological evaluation of novel urea-and guanidine-based derivatives for the treatment of obesity-related hepatic steatosis

Molecules

Volumn 19, Issue 5, 2014, Pages 6163-6183

  Liang, Xiaolin ^a   Pei, Heying ^a   Ma, Liang ^a   Ran, Yan ^a   Chen, Jinying ^a   Wang, Guangcheng ^a   Chen, Lijuan ^a  

^a SICHUAN UNIVERSITY   (China)

Author keywords

Diet induced obesity; Hepatic steatosis; Leptin; Urea and guanidine based

Indexed keywords

GUANIDINE; LEPTIN; UREA;

3T3 CELL LINE; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; CHEMISTRY; COMPLICATION; DRUG EFFECTS; FATTY LIVER; GENE EXPRESSION REGULATION; HUMAN; LIPID DIET; LIPID METABOLISM; MOUSE; OBESITY; SYNTHESIS;

3T3-L1 CELLS; ANIMALS; DIET, HIGH-FAT; FATTY LIVER; GENE EXPRESSION REGULATION; GUANIDINE; HUMANS; LEPTIN; LIPID METABOLISM; MICE; OBESITY; UREA;

EID: 84901394215     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules19056163     Document Type: Article

References (37)

1. Bray, G.A. Obesity: The disease. J. Med. Chem. 2006, 49, 4001-4007.
2. Kelly, T.; Yang, W.; Chen, C.-S.; Reynolds, K.; He, J. Global burden of obesity in 2005 and projections to 2030. Int. J. Obesity. 2008, 32, 1431-1437.
3. O'Brien, P.E.; Dixon, J.B. The extent of the problem of obesity. Am. J. Surg. 2002, 184, S4-S8.
4. Pi-Sunyer, F.X. Medical hazards of obesity. Ann. Intern. Med. 1993, 119, 655-660.
5. Feneberg, A.; Malfertheiner, P. Epidemic trends of obesity with impact on metabolism and digestive diseases. Digest. Dis. 2012, 30, 143-147.
6. Schindhelm, R.K.; Diamant, M.; Dekker, J.M.; Tushuizen, M.E.; Teerlink, T.; Heine, R.J. Alanine aminotransferase as a marker of non-Alcoholic fatty liver disease in relation to type 2 diabetes mellitus and cardiovascular disease. Diabetes. Metab. Res. Rev. 2006, 22, 437-443.
7. Bacon, B.R.; Farahvash, M.J.; Janney, C.G.; Neuschwander-Tetri, B.A. Nonalcoholic steatohepatitis: An expanded clinical entity. Gastroenterology 1994, 107, 1103-1109.
8. Henao-Mejia, J.; Elinav, E.; Jin, C.; Hao, L.; Mehal, W.Z.; Strowig, T.; Thaiss, C.A.; Kau, A.L.; Eisenbarth, S.C.; Jurczak, M.J.; et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482, 179-186.
9. Angulo, P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002, 346, 1221-1231.
10. Browning, J.D.; Horton, J.D. Molecular mediators of hepatic steatosis and liver injury. J. Clin. Invest. 2004, 114, 147-152.
11. Jéquier, E. Leptin signaling, adiposity, and energy balance. Ann. N. Y. Acad. Sci. 2002, 967, 379-388.
12. Børbaek, C.; Kahn, B.B. Leptin signaling in the central nervous system and the periphery. Prog. Horm. Res. 2004, 59, 305-331.
13. Dellas, C.; Lankeit, M.; Reiner, C.; Schäfer, K.; Hasenfuβ, G.; Konstantinides, S. BMI-independent inverse relationship of plasma leptin levels with outcome in patients with acute pulmonary embolism. Int. J. Obes. (Lond.) 2013, 37, 204-210.
14. Considine, R.V.; Sinha, M.K.; Heiman, M.L.; Kriauciunas, A.I.; Stephens, T.W.; Nyce, M.R.; Ohannesian, J.P.; Marco, C.C.; Mckee, L.J.; Bauer, T.L.; et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N. Engl. J. Med. 1996, 334, 292-295.
15. Roberts, E.A. Pediatric nonalcoholic fatty liver disease (NAFLD): A "growing" problem? J. Hepatol. 2007, 46, 1133-1142.
16. Pérez, C.; Fernández-Galaz, C.; Fernández- Agulló, T.; Arribas, C.; Andrés, A.; Ros, M.; Carrascosa, J.M. Leptin impairs insulin signaling in rat adipocytes. Diabetes 2004, 53, 347-353.
17. Cohen, B.; Novick, D.; Rubinstein, M. Modulation of insulin activities by leptin. Science 1996, 274, 1185-1188.
18. Muller, G.; Ertl, J.; Gerl, M.; Preibish, G. Leptin impairs metabolic actions of insulin in isolated rat adipocytes. J. Biol. Chem. 1997, 272, 10585-10593.
19. Valerio, N.; Melania, M.; Paolo, C.; Vincenzo, D.; Rita, D.; Fiorella, P.; Roberto, C.; Donatella, G.; Matilde, M. Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-Alcoholic fatty liver disease. Eur. J. Endocrinol. 2006, 155, 735-743.
20. Lewis, G.F.; Carpentier, A.; Adeli, K.; Giacca, A. Disordered fat storage and mobilization in the pathogenesis of insulin resistance and type 2 diabetes. Endocr. Rev. 2002, 23, 201-229.
21. Leclercq, I.A.; Farrell, G.C.; Schriemer, R.; Robertson, G.R. Leptin is essential for the hepatic fibrogenic response to chronic liver injury. J. Hepatol. 2002, 37, 206-213.
22. Imajo, K.; Fujita, K.; Yoneda, M.; Nozaki, Y.; Ogawa, Y.; Shinohara, Y.; Kato, S.; Mawatari, H.; Shibata, W.; Kitani, H.; et al. Hyperresponsivity to low-dose endotoxin during progression to nonalcoholic steatohepatitis is regulated by leptin-mediated signaling. Cell. MeTable 2012, 16, 44-54.
23. Patel, K.; Muir, A., McHutchison, J.G.; Patton, H.M. A link between leptin and steatosis in chronic hepatitis C? Time to weigh up the fats. Am. J. Gastroenterol. 2003, 98, 952-955.
24. Freemark, M.; Bursey, D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics 2001, 107, E55.
25. Duseja, A.; Das, A.; Dhiman, R.K.; Chawla, Y.K.; Thumburu, K.T.; Bhadada, S.; Bhansali, A. Metformin is effective in achieving biochemical response in patients with nonalcoholic fatty liver disease (NAFLD) not responding to lifestyle interventions. Ann. Hepatol. 2007, 6, 222-226.
26. Stein, L.L.; Dong, M.H.; Loomba, R. Insulin Sensitizers in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Current Status. Adv. Ther. 2009, 26, 893-907.
27. Plosker, GL.; Faulds, D. Troglitazone: A review of its use in themanagement of type 2 diabetes mellitus. Drugs 1999, 57, 409-438.
28. Pereira, C.V.; Moreira, A.C.; Pereira, S.P.; Machado, N.G.; Carvalho, F.S.; Sardao, V.A.; Oliveira, P.J. Investigating Drug-induced Mitochondrial Toxicity: A Biosensor to Increase Drug Safety? Curr. Drug Saf. 2009, 4, 34-54.
29. Venier, O.; Pascal, C.; Braun, A.; Namane, C.; Mougenot, P.; Crespin, O.; Pacquet, F.; Mougenot, C.; Monseau, C.; Onofri, B.; et al. Pyrrolidine-pyrazole ureas as potent and selective inhibitors of 11β-hydroxysteroid- dehydrogenase type 1. Bioorg. Med. Chem. Lett. 2011, 21, 2244-2251.
30. Sophie, P.; Peter, R.M.; Steve, S.; Veronique, G. Fluorine in medicinal chemistry. Chem. Soc. Rev. 2008, 37, 320-330.
31. Hoffler, U.; Hobbie, K.; Wilson, R.; Bai, R.; Rahman, A.; Malarkey, D.; Travlos, G.; Ghanayem, B.I. Diet-induced obesity is associated with hyperleptinemia, hyperinsulinemia, hepatic steatosis, and glomerulopathy in C57Bl/6J mice. Endocrine 2009, 36, 311-325.
32. Kang, H.S.; Okamoto, K.; Takeda, Y.; Beak, J.Y.; Gerrish, K.; Bortner, C.D.; DeGraff, L.M.; Wada, T.; Xie, W.; Jetten, A.M. Transcriptional profiling reveals a role for RORa in regulating gene expression in obesity-Associated inflammation and hepatic steatosis. Physiol. Genomics 2011, 43, 818-828.
33. Adachi, M.; Brenner, D.A. High molecular weight adiponectin inhibits proliferation of hepatic stellate cells via activation of adenosine monophosphate-Activated protein kinase. Hepatology 2008, 47, 677-685.
34. Polyzos, S.A.; Kountouras, J.; Zavos, C.; Tsiaousi, E. The role of adiponectin in the pathogenesis and treatment of non-Alcoholic fatty liver disease. Diabetes Obes. Metab. 2010, 12, 365-383.
35. Wang, Y.; Zhou, M.; Lam, K.S.; Xu, A. Protective roles of adiponectin in obesity-related fatty liver diseases: Mechanisms and therapeutic implications. Arq. Bras. Endocrinol. Metabol. 2009, 53, 201-212.
36. Hench, J.; Hench, I.B.; Pujol, C.; Ipsen, S.; Brodesser, S.; Mourier, A.; Tolnay, M.; Frank, S.; Trifunovic, A. A tissue-specific approach to the analysis of metabolic changes in Caenorhabditis elegans. PLoS One 2011, 6, e28417.
37. Cook, H.C. Origins of Tinctorial methods in histology. J. Lin. Pathol. 1997, 50, 716-720.